Understand the source comparison
SS-LUP-332 History: [Compound Type] Comparison
Different AMPK activators and exercise mimetics have followed distinct developmental paths, each shaped by their mechanism and selectivity profile. This table compares SS-LUP-332 to three earlier compounds that attempted similar metabolic effects. SS-LUP-332 A
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different AMPK activators and exercise mimetics have followed distinct developmental paths, each shaped by their mechanism and selectivity profile. This table compares SS-LUP-332 to three earlier compounds that attempted similar metabolic effects.
- SS-LUP-332
- AMPK α1 isoform-selective activator via allosteric binding at α1/β2 interface
- 4–6-fold preferential activation in skeletal muscle vs cardiac tissue
- Limited oral bioavailability (requires injection or novel delivery in most rodent models)
- Metabolic research, endurance studies, mitochondrial biogenesis investigations
- First exercise mimetic to achieve meaningful tissue selectivity—addresses the cardiac risk that ended earlier candidates
- AICAR
- AMP mimetic—directly activates AMPK by mimicking AMP binding to γ subunit
- Non-selective—activates AMPK in all tissues equally
- Cardiac hypertrophy and arrhythmia risk with chronic use; banned by WADA in 2011
- Positive control in metabolic studies; rarely used in new research due to safety profile
- Proof-of-concept for exercise mimetics but failed due to lack of selectivity
- GW501516 (Cardarine)
- PPARδ agonist—indirectly increases fatty acid oxidation and mitochondrial gene expression
- Moderate selectivity (higher expression in muscle and adipose)
- Accelerated tumor growth in rodent models at high doses; development halted in 2007
- Rarely used in legitimate research due to carcinogenicity findings
- Effective metabolic modulator but unacceptable safety profile ended development
- Metformin
- Complex mechanism—AMPK activation via inhibition of mitochondrial complex I
- Non-selective but well-tolerated due to low potency
- Requires high doses (1000–2000 mg in humans); GI side effects common; modest endurance effects
- Type 2 diabetes treatment; longevity research; metabolic health studies
- Safe and validated but lacks the potency and targeted effects of newer compounds like SS-LUP-332